Ensomafusp Alfa

**Semantic type:** Pharmacologic Substance

**Definition:** An immunotherapeutic agent that targets both CD19 and 4-1BB (CD137; tumor necrosis factor receptor superfamily member 9; TNFRSF9), with potential immunostimulatory and antineoplastic activity. Upon administration, ensomafusp alfa simultaneously binds to CD19 and 4-1BB, thereby crosslinking CD19 and 4-1BB positive cells. This triggers, through the 4-1BB ligand, the proliferation and activation of natural killer cells (NKs) and T-cells. This results in an enhanced cytotoxic T-lymphocyte (CTL)-mediated immune response against CD19-expressing tumor cells. 4-1BB, a surface glycoprotein of the tumor necrosis factor receptor superfamily (TNFRSF), is an inducible costimulatory receptor that plays a key role in T-cell proliferation, survival and cytolytic activity.

**Synonyms:** - CD19-4-1BBL RO7227166 - CD19-targeted 4-1BB Ligand RO7227166 - ENGLUMAFUSP ALFA - RG 6076 - RG-6076 - RG6076 - RO 7227166 - RO-7227166 - RO7227166